Compare Ally Financial Inc (ALLY) vs Hims and Hers Health Inc (HIMS) Price & Performance

Ally Financial (ALLY) trades at $43.72, down 0.77% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 10.29 and P/B of 0.98, trading below analyst consensus target of $54.40. Recent Q2 2026 earnings missed expectations, causing a 2.4% decline, though revenue grew 10% year-over-year. The company maintains strong institutional support with 68% analyst buy ratings.

Outlook remains cautiously optimistic given the discounted valuation and solid fundamentals, though near-term pressure exists from recent earnings miss and insider selling. Key risks include credit quality concerns, interest rate sensitivity, and competitive pressures in auto lending. The 24% upside to consensus target suggests potential reward for patient investors despite technical weakness.

Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.

The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.